Effects of dopaminergic replacement therapy on motor speech disorders in Parkinson's disease: longitudinal follow-up study on previously untreated patients

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F16%3A10323005" target="_blank" >RIV/00064165:_____/16:10323005 - isvavai.cz</a>

Alternative codes found

RIV/68407700:21230/16:00242453 RIV/00216208:11110/16:10323005

Result on the web

<a href="http://dx.doi.org/10.1007/s00702-016-1515-8" target="_blank" >http://dx.doi.org/10.1007/s00702-016-1515-8</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s00702-016-1515-8" target="_blank" >10.1007/s00702-016-1515-8</a>

Result language

angličtina

Original language name

Effects of dopaminergic replacement therapy on motor speech disorders in Parkinson's disease: longitudinal follow-up study on previously untreated patients

Original language description

Although speech disorders represent an early and common manifestation of Parkinson's disease (PD), little is known about their progression and relationship to dopaminergic replacement therapy. The aim of the current study was to examine longitudinal motor speech changes after the initiation of pharmacotherapy in PD. Fifteen newly-diagnosed, untreated PD patients and ten healthy controls of comparable age were investigated. PD patients were tested before the introduction of antiparkinsonian therapy and then twice within the following 6 years. Quantitative acoustic analyses of seven key speech dimensions of hypokinetic dysarthria were performed. At baseline, PD patients showed significantly altered speech including imprecise consonants, monopitch, inappropriate silences, decreased quality of voice, slow alternating motion rates, imprecise vowels and monoloudness. At follow-up assessment, preservation or slight improvement of speech performance was objectively observed in two-thirds of PD patients within the first 3-6 years of dopaminergic treatment, primarily associated with the improvement of stop consonant articulation. The extent of speech improvement correlated with l-dopa equivalent dose (r = 0.66, p = 0.008) as well as with reduction in principal motor manifestations based on the Unified Parkinson's Disease Rating Scale (r = MINUS SIGN 0.61, p = 0.02), particularly reflecting treatment-related changes in bradykinesia but not in rigidity, tremor, or axial motor manifestations. While speech disorders are frequently present in drug-naive PD patients, they tend to improve or remain relatively stable after the initiation of dopaminergic treatment and appear to be related to the dopaminergic responsiveness of bradykinesia.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FH - Neurology, neuro-surgery, nuero-sciences

OECD FORD branch

—

Project

<a href="/en/project/NV15-28038A" target="_blank" >NV15-28038A: Speech disorders and analysis of their mechanisms in Parkinson's disease and other movement disorders.</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2016

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Journal of Neural Transmission

ISSN

0300-9564

e-ISSN

—

Volume of the periodical

123

Issue of the periodical within the volume

4

Country of publishing house

AT - AUSTRIA

Number of pages

9

Pages from-to

379-387

UT code for WoS article

000373162500003

EID of the result in the Scopus database

2-s2.0-84957539092